Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

Eton Pharmaceuticals, GeoVax Labs And 2 Other Penny Stocks Insiders Are Aggressively Buying

Published 26/09/2022, 13:48
© Reuters.  Eton Pharmaceuticals, GeoVax Labs And 2 Other Penny Stocks Insiders Are Aggressively Buying

The Nasdaq Composite dropped by around 200 points on Friday. Investors, meanwhile, focused on some notable insider trades.

When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.3

OPKO Health

  • The Trade: OPKO Health, Inc. (NASDAQ: OPK) 10% owner Frost Gamma Investments Trust bought a total of 50,000 shares at an average price of $1.90. To acquire these shares, it cost around $94.84 thousand.
  • What’s Happening: OPKO Health, last month, posted a Q2 loss of $0.14 per share.
  • What OPKO Health Does: OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs.
  • The Trade: GeoVax Labs, Inc. (NASDAQ: GOVX) Director Randal Chase acquired a total of 10,000 shares at an average price of $1.10. The insider spent around $11 thousand to buy those shares.
  • What’s Happening: The company’s stock has dipped over 70% since the start of the year.
  • What GeoVax Labs Does: Geovax Labs Inc is us-based clinical-stage biotechnology company. It is engaged in developing immunotherapies and vaccines against cancers and infectious diseases using a novel patented Modified Vaccinia Ankara-Virus Like Particle (GV-MVA-VLP) vector vaccine platform.

Don’t forget to check out our premarket coverage here .

Eton Pharmaceuticals

  • The Trade: Eton Pharmaceuticals, Inc. (NASDAQ: ETON) CEO Sean Brynjelsen acquired a total of 10,000 shares at an average price of $2.10. To acquire these shares, it cost around $21.04 thousand.
  • What’s Happening: Eton Pharmaceuticals, last month, posted a Q2 loss of $0.06 per share.
  • What Eton Pharmaceuticals Does: Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company.
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .
  • The Trade: Great Elm Group, Inc. (NASDAQ: GEG) 10% owner BC Advisors LLC acquired a total of 13,463 shares at an average price of $2.05. The insider spent $27.59 thousand to buy those shares.
  • What’s Happening: Great Elm Group recently posted Q4 sales of $18.10 million.
  • What Great Elm Group Does: Great Elm Group Inc operates as a holding company. The company operates in two business lines including durable medical equipment and investment management.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.